Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:
Coronavirus COVID-19 Research & Development BioPharmaceutical

Coronavirus Update: Imperial And Morningside Form Social Enterprise For COVID-19 Vaccine

Plus Updates From Daiichi And Shionogi

Executive Summary

London university ready to launch clinical trials of vaccine based on self-amplifying RNA technology shortly.

You may also be interested in...



Coronavirus Update: Russia Plans First Vaccinations In October

Concern and skepticism about Russia's rapid vaccine roll out. Meanwhile Japan is latest to reach deal with Pfizer/BioNTech.

Coronavirus Update: How Should Remdesivir Be Priced? ICER Are In Two Minds

Independent drug cost watchdog updates its twin pricing estimates for Gilead's drug - but dexamethasone could tip the balance again.

Coronavirus Update: Amid Fears Of Trump Pressure, Fauci Warns Of Rushing Vaccine Authorization

Anthony Fauci says a hasty emergency use authorization for a vaccine would be a mistake - and the FDA commissioner will not be drawn on timelines.

Table

View full table

Related Content

Scrip
Scrip
Scrip

Topics

Related Companies

Tags:
Coronavirus COVID-19 Research & Development BioPharmaceutical
Latest Headlines

Takeda, Astellas Found New JV To Support Japanese Bioventures

Ipsen Expands Its Rare Neurological Disease Pipeline With Skyhawk Deal

Deal Watch: Six Small Biopharma Mergers Reflect Recent Trend

BMS Fast Tracks CAR-T Manufacturing With Cellares Deal

See All
UsernamePublicRestriction

Register

SC142361

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By